ArticleMicrobial cell factories2015
Metabolic engineering of Escherichia coli into a versatile glycosylation platform: production of bio-active quercetin glycosides.
Article in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.International journal of molecular sciences · 2024Pooled it
- Efficient whole-cell biotransformation for gastrodin production via glycosyltransferase engineering and process optimization.Synthetic and systems biotechnology · 2026Article
- Metabolic engineering of Escherichia coli strains for the in vivo phosphorylase-mediated synthesis of disaccharides.Microbial cell factories · 2026Article
- Expanding Steroid Glycodiversity: Tandem Steroid Glucosylation and Acetylation via Enzymatic Cascade.International journal of molecular sciences · 2026Article
- Engineering a Robust Escherichia coli W Platform for Scalable Production of Flavonoid-O-Glucosides.Microbial biotechnology · 2025Article
- A Comprehensive Review of the Effects ofPreventive nutrition and food science · 2025Review
- Efficient production of hydroxysalidroside inSynthetic and systems biotechnology · 2025Article
- Overexpression ofHeliyon · 2024Article
- Functional characterization and structural basis of a reversible glycosyltransferase involves in plant chemical defence.Plant biotechnology journal · 2023Article
- The parallel biosynthesis routes of hyperoside from naringenin inHorticulture research · 2023Article
- Microbial production of nutraceuticals: Metabolic engineering interventions in phenolic compounds, poly unsaturated fatty acids and carotenoids synthesis.Journal of food science and technology · 2023Review
- Review
- An efficient preparation and biocatalytic synthesis of novel C-glycosylflavonols kaempferol 8-C-glucoside and quercetin 8-C-glucoside through using resting cells and macroporous resins.Biotechnology for biofuels and bioproducts · 2022Article
- Untargeted Metabolomics Profiling Reveals Beneficial Changes in Milk of Sows Supplemented with Fermented Compound Chinese Medicine Feed Additive.Animals : an open access journal from MDPI · 2022Article
- Hyperoside as a Potential Natural Product Targeting Oxidative Stress in Liver Diseases.Antioxidants (Basel, Switzerland) · 2022Review
- Multi-strategy engineering unusual sugar TDP-l-mycarose biosynthesis to improve the production of 3-Synthetic and systems biotechnology · 2022Article
- Metabolic Engineering ofMicroorganisms · 2022Article
- Glycosyltransferases: Mining, engineering and applications in biosynthesis of glycosylated plant natural products.Synthetic and systems biotechnology · 2022Article
- May phytophenolics alleviate aflatoxins-induced health challenges? A holistic insight on current landscape and future prospects.Frontiers in nutrition · 2022Review
- Undifferentiated In Vitro CulturedPlants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFlavonoids are bio-active specialized plant metabolites which mainly occur as different glycosides. Due to the increasing market demand, various biotechnological approaches have been developed which use Escherichia coli as a microbial catalyst for the stereospecific glycosylation of flavonoids. Despite these efforts, most processes still display low production rates and titers, which render them unsuitable for large-scale applications.
resultsIn this contribution, we expanded a previously developed in vivo glucosylation platform in E. coli W, into an efficient system for selective galactosylation and rhamnosylation. The rational of the novel metabolic engineering strategy constitutes of the introduction of an alternative sucrose metabolism in the form of a sucrose phosphorylase, which cleaves sucrose into fructose and glucose 1-phosphate as precursor for UDP-glucose. To preserve these intermediates for glycosylation purposes, metabolization reactions were knocked-out. Due to the pivotal role of UDP-glucose, overexpression of the interconverting enzymes galE and MUM4 ensured the formation of both UDP-galactose and UDP-rhamnose, respectively. By additionally supplying exogenously fed quercetin and overexpressing a flavonol galactosyltransferase (F3GT) or a rhamnosyltransferase (RhaGT), 0.94 g/L hyperoside (quercetin 3-O-galactoside) and 1.12 g/L quercitrin (quercetin 3-O-rhamnoside) could be produced, respectively. In addition, both strains showed activity towards other promising dietary flavonols like kaempferol, fisetin, morin and myricetin.
conclusionsTwo E. coli W mutants were engineered that could effectively produce the bio-active flavonol glycosides hyperoside and quercitrin starting from the cheap substrates sucrose and quercetin. This novel fermentation-based glycosylation strategy will allow the economically viable production of various glycosides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.